Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, has launched Zoledronic Acid Injection 5 mg, the generic form of the bisphosphonate Reclast, in a ready-to-use premix IV bag presentation. As with all products in Sagent's portfolio, Zoledronic Acid features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
"Sagent is pleased to offer our customers Zoledronic Acid Injection 5 mg in an enhanced packaging option, a ready-to-use premix bag, which can help reduce the risk of contamination and reconstitution errors," said Jeffrey M Yordon, chief executive officer and chairman of the board of Sagent.
Zoledronic Acid 5 mg is indicated for the treatment of Paget's disease of bone in men and women.
Sagent Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.